Aug 05, 2022
Candel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
Additional Formats
Aug 01, 2022
Candel Therapeutics Appoints Three New Members to its Board of Directors
Additional Formats
May 26, 2022
Candel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer
Additional Formats
May 18, 2022
Candel Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
Additional Formats
May 12, 2022
Candel Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
Additional Formats
Apr 27, 2022
Candel Therapeutics to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Additional Formats
Mar 29, 2022
Candel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Highlights
Additional Formats
Mar 02, 2022
Candel Therapeutics Appoints Seshu Tyagarajan, Ph.D., RAC, as Chief Technical and Development Officer
Additional Formats
Mar 01, 2022
Candel Therapeutics Announces $25 Million Non-dilutive Debt Financing Agreement with Silicon Valley Bank
Additional Formats
Feb 03, 2022
Candel Therapeutics Appoints Dr. Francesca Barone as Chief Scientific Officer
Additional Formats
Displaying 1 - 10 of 11